You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK):阿普唑侖片通過仿製藥一致性評價

格隆匯11月30日丨上海醫藥(02607.HK)發佈公吿,近日,公司全資子公司上海上藥信誼藥廠有限公司收到國家藥品監督管理局頒發的關於阿普唑侖片的《藥品補充申請批准通知書》,該藥品通過仿製藥一致性評價。

阿普唑侖片主要用於焦慮、緊張、激動,也可用於催眠或焦慮的輔助用藥,也可作為抗驚恐藥,並能緩解急性酒精戒斷症狀,由PHARMACIAANDUPJOHNCO研發,最早於1981年在美國上市。2022年10月,上藥信誼就該藥品仿製藥一致性評價向國家藥監局提出申請並獲受理。

截至本公吿日,公司針對該藥品的一致性評價已投入研發費用約人民幣619萬元。截至本公吿日,中國境內該藥品的主要生產廠家包括山東信誼製藥有限公司、江蘇恩華藥業股份有限公司、齊魯製藥有限公司等。

IQVIA數據庫顯示,2022年該藥品醫院採購金額為人民幣17,356萬元。2022年,上藥信誼該藥品的銷售收入為人民幣2,073萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account